Patents Assigned to Universite Catholique de Louvain
-
Publication number: 20240415895Abstract: A composition including one or more bacteria selected from the genus Parabacteroides and/or an extract thereof and/or metabolites thereof. Also, the use of this composition in methods of preventing and/or treating reward dysregulation disorders, including mental disorders, neurological disorders, and combinations thereof, by administering this composition to an individual in need thereof.Type: ApplicationFiled: July 20, 2022Publication date: December 19, 2024Applicant: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Amandine EVERARD, Alice DE WOUTERS D'OPLINTER, Geoffroy Olivier Ludovic MALLARET, Patrice CANI
-
Publication number: 20240318166Abstract: Plasmid DNA can be efficiently recovered from bacterial cells when producing plasmid DNA using E. coli. Provided is a method for producing plasmid DNA including the following steps (a) to (c): (a) a step of preparing E. coli, which has a mutation in a gene region associated with maintaining outer membrane properties and has a desired plasmid; (b) a step of culturing E. coli of (a); and (c) a step of recovering a desired plasmid from bacterial cells after culture.Type: ApplicationFiled: January 16, 2024Publication date: September 26, 2024Applicants: KANEKA CORPORATION, KANEKA EUROGENTEC S.A., Universite catholique de LouvainInventors: Tomohisa Tokunaga, Tozo Nishiyama, Kazunobu Minakuchi, Seung Hyun Cho, Jean-Francois Collet, Michael Deghelt
-
Publication number: 20240281965Abstract: A computer-implemented method for determining a risk of having or developing steatohepatitis and/or a complication thereof in a subject. The method includes the steps of: receiving at least one image of the subject and at least one clinical and/or biological data, both previously obtained from the subject; calculating a score of fat infiltration heterogeneity on the at least one image based on at least one radiomic feature obtained for a region of interest including at least one skeletal muscle; combining the calculated score of fat infiltration heterogeneity with the at least one clinical and/or biological data previously obtained from the subject; determining a risk for the subject of having or developing steatohepatitis and/or a complication thereof based on the combination of the calculated score of fat infiltration heterogeneity with the at least one clinical and/or biological data.Type: ApplicationFiled: June 9, 2022Publication date: August 22, 2024Applicant: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Maxime NACHIT, Isabelle LECLERCQ
-
Patent number: 12032047Abstract: A radiofrequency transducer assembly includes an antenna structure of the birdcage type. This antenna structure has longitudinally extending segments, which are arranged in a cylindrical configuration around a center axis, and at least one transversally oriented circular electrical coupling between the longitudinally extending segments. An electrically conductive shield surrounds the antenna structure of the birdcage type. The radiofrequency transducer assembly comprises a pair of electrically conductive bridges between a longitudinally extending segment of the antenna structure and the electrically conductive shield, which thereby jointly form an inductive loop.Type: GrantFiled: October 6, 2020Date of Patent: July 9, 2024Assignee: UNIVERSITE CATHOLIQUE DE LOUVAINInventors: Christophe Craeye, Chan-Sun Park, Denis Tihon
-
Patent number: 11963892Abstract: A prosthesis or orthosis for a joint, such as an ankle, which includes a first body, a second body, and an articulated joint between the first and second bodies, the articulated joint allowing the rotation of the first and second bodies with respect to one another around a joint rotation axis. It further includes a locking mechanism configured to selectively lock the rotation between the first and second bodies in one direction, when it is in a locked configuration, and a transmission mechanism such that a rotation of the joint rotation axis generates a movement of a lockable part of the locking mechanism. The axis of the movement of the lockable part is shifted relative to the joint rotation axis and the transmission mechanism includes a reducer configured to reduce effort to lock the rotation of the first body with respect to the second body.Type: GrantFiled: August 23, 2019Date of Patent: April 23, 2024Assignee: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Bruno Dehez, François Heremans, Renaud Ronsse
-
Publication number: 20240116987Abstract: A polypeptide including the amino acid sequence of formula (I): GX1MMX2LQHGSX3X4X5QTP. These polypeptides modulate the activity of the native tetrameric lactate dehydrogenase LDH-1, by inhibiting the tetramerization of its subunits. Also, the therapeutic use of these polypeptides as a medicament, in particular for the prevention and/or the treatment of cancer.Type: ApplicationFiled: February 1, 2022Publication date: April 11, 2024Applicant: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Pierre SONVEAUX, Raphaël FREDERICK, Léopold THABAULT, Maxime LIBERELLE
-
Publication number: 20240002246Abstract: A continuous process for the production of sodium bicarbonate crystals from the carbon dioxide of a gas stream including an absorption step of the carbon dioxide from a gas stream into an aqueous solution including a sodium carbonate salt to produce an aqueous solution of sodium bicarbonate, then a crystallization step of the sodium bicarbonate salt obtained at the first step. A system for the production of sodium bicarbonate crystals from carbon dioxide of a gas stream including a control unit, an absorption unit and a crystallization unit.Type: ApplicationFiled: December 3, 2021Publication date: January 4, 2024Applicant: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Patricia LUIS ALCONERO, Vida SANG SEFIDI, Mar GARCIA ALVAREZ, Marie-Charlotte SPARENBERG
-
Publication number: 20240000794Abstract: Lactam or lactone derivatives of formula Ia: or a pharmaceutically acceptable salt or solvate thereof, wherein X1 is NH or O; X2 is —OH, —O-alkyl, —NH2, an amino acid group or a peptide group, wherein the amino acid group or peptide group is linked to the carbonyl group by its N-terminal residue; Z1 is S, SO, SO2, O, CR3 or NR4; and R1, R2, R3 and R4 each independently are H, alkyl or aryl. Also, the use of lactam or lactone derivatives of formula Ia in treating a disease caused by a viral infection, especially a coronavirus infection and/or a viral respiratory infection, such as COVID-19 caused by SARS-CoV-2.Type: ApplicationFiled: November 19, 2021Publication date: January 4, 2024Applicant: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Patrice SOUMILLION, Pierre GALKA
-
Publication number: 20230411309Abstract: A structure for an RF device provided with a semiconductor region coated with a heterogeneous dielectric region, the heterogeneous dielectric region including, in at least one first direction parallel to a main plane of the substrate, an alternation of first areas made of a first dielectric material with positive fixed charges and of second dielectric areas made of a second dielectric material with negative fixed charge in order to create an alternation of polarity allowing preventing the formation of a parasitic conduction layer in the semiconductor region.Type: ApplicationFiled: June 19, 2023Publication date: December 21, 2023Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE CATHOLIQUE DE LOUVAINInventors: Louis HUTIN, Maxime MOULIN, Thibaud FACHE, Christophe PLANTIER, Jean-Pierre RASKIN, Martin RACK
-
Publication number: 20230372412Abstract: A bacterium belonging to a novel bacterial genus, Dysosmobacter. Also, the therapeutic, nutraceutical and cosmetic use thereof. The uses include methods for treating a disorder, promoting weight loss, decreasing food intake, increasing muscle mass, decreasing fat mass, increasing satiety, and/or decreasing weight gain associated with food intake in a subject, including administering to the subject at least one isolated bacterium belonging to the genus Dysosmobacter and/or a variant thereof and/or fragments thereof.Type: ApplicationFiled: May 15, 2023Publication date: November 23, 2023Applicant: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Patrice CANI, Tiphaine LE ROY
-
Publication number: 20230340035Abstract: Genetically modified gram-negative bacteria, in particular E. coli, that are oversensitive to lysis. These bacteria are therefore useful to improve the yield of nucleic acid extraction, preferably extra-genomic nucleic acid extraction (e.g. plasmid), and/or the yield of a polypeptide, preferably encoded by an extra-genomic nucleic acid. In practice, the strains of E. coli are engineered with a combination of at least 2 mutated genes altering the envelop integrity. More particularly, at least one mutated gene is ompA and at least one mutated gene is a gene involved in Lpp functionality, such as, e.g., the lpp gene, the ybiS gene, the ycfS gene and the erfK gene. These combinations also include mutations in genes that are homologue to the ompA gene, and/or the lpp gene.Type: ApplicationFiled: January 18, 2021Publication date: October 26, 2023Applicant: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Jean-François COLLET, Michaël DEGHELT, Seung Hyun CHO
-
Conditioned medium from human adult liver stem cells and its use in the treatment of liver disorders
Patent number: 11793837Abstract: The invention relates to cell-free compositions obtained by culturing adult-derived human liver stem/progenitor cells (ADHLSC) in cell culture medium and isolating the resulting conditioned medium (ADHLSC-CM) that has advantageous properties, such as anti-fibrotic effects. ADHLSC-CM, compositions based on ADHLSC-CM, and other related and derived products, can be used in cell culture processes or as a medicament, more particularly for the treatment of diseases involving organ injury, organ failure, in organ or cell transplantation or the pathological disruption, inflammation, degeneration, and/or proliferation of cells within a tissue or an organ, in particular within liver.Type: GrantFiled: November 25, 2020Date of Patent: October 24, 2023Assignee: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Mustapha Najimi, Etienne Sokal, Silvia Berardis -
Patent number: 11799295Abstract: An example device includes a processor configured to receive a plurality of voltage values representing respective voltage magnitudes at voltage nodes in a first portion of a power system and determine, for each voltage node, a respective value of first and second voltage-constraint coefficients. The processor is also configured to receive a power value corresponding to a connection point of the first portion of the power system with a second portion of the power system and determine for the connection point, a respective value of first and second power-constraint coefficients. The processor is also configured to cause at least one energy resource connected to the first portion of the power system to modify an output power of the at least one energy resource based on the value of the first and second voltage-constraint coefficients for each voltage node and the value of the first and second power-constraint coefficients.Type: GrantFiled: February 5, 2021Date of Patent: October 24, 2023Assignees: Alliance for Sustainable Energy, LLC, Universite Catholique de LouvainInventors: Emiliano Dall'Anese, Andrey Bernstein, Andrea Simonetto
-
Patent number: 11690879Abstract: A bacterium belonging to a novel bacterial genus, Dysosmobacter. Also, the therapeutic, nutraceutical and cosmetic use thereof. The uses include methods for treating a disorder, promoting weight loss, decreasing food intake, increasing muscle mass, decreasing fat mass, increasing satiety, and/or decreasing weight gain associated with food intake in a subject, including administering to the subject at least one isolated bacterium belonging to the genus Dysosmobacter and/or a variant thereof and/or fragments thereof.Type: GrantFiled: July 10, 2019Date of Patent: July 4, 2023Assignee: UNIVERSITÈ CATHOLIQUE DE LOUVAINInventors: Patrice Cani, Tiphaine Le Roy
-
Publication number: 20230165836Abstract: The present invention relates to the treatment of cancer. In particular, the invention relates to the therapeutic use of alpha-2 adrenergic receptor agonists for the treatment of cancer. More particularly, apraclonidine, clonidine, guanfacine and guanabenz, which are alpha-2 adrenergic receptor agonists, are all capable of efficiently reducing the growth of solid tumors. The effect is immune-mediated and is abolished in the presence of an alpha-2 antagonist or in mice that are knockout for the alpha-2 adrenergic receptor.Type: ApplicationFiled: April 21, 2021Publication date: June 1, 2023Applicant: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Benoît VAN DEN EYNDE, Jingjing ZHU
-
Publication number: 20230149360Abstract: The present invention relates to the therapeutic use of alpha-2 adrenergic receptor agonists in the prevention and/or treatment of spleen disorders, in particular splenomegaly. The inventors showed that clonidine, guanabenz and romifidine efficiently reduced the spleen weight of animal models with cancer-induced splenomegaly, immunization-induced splenomegaly or splenomegaly induced by myelofibrosis.Type: ApplicationFiled: April 21, 2021Publication date: May 18, 2023Applicant: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Benoît VAN DEN EYNDE, Jingjing ZHU
-
Patent number: 11613762Abstract: The present invention relates generally to the field of plant molecular biology and relates to plants having a modified lipid metabolism and to methods for making such modified plants. In particular, the invention provides modified plants and parts thereof, including seeds, having an increased level of triacylglycerol (TAG), by means of a seed-specific expression in seed tissues during seed filling of a nucleic acid encoding a translocator protein (TSPO) in said modified plants or parts thereof. The invention further relates to methods for modulating lipid metabolism in plants and for producing plants with a modified lipid metabolism. The invention also provides constructs, vectors and host cells useful in the methods of the invention, and further relates to products obtained from the modified plants.Type: GrantFiled: August 24, 2018Date of Patent: March 28, 2023Assignees: UNIVERSITÉ CATHOLIQUE DE LOUVAIN, UNIVERSITE DE BORDEAUX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Henri Batoko, Patrick Moreau
-
Patent number: 11538689Abstract: A substrate has a front side including an electrical circuit and a rear side including an exposed zone that faces the electrical circuit. In an electrochemical treatment step, an electrical potential is laterally applied at least to the exposed zone of the rear side of the substrate, while the exposed zone is in contact with a chemically reactive substance. The electrical potential causes a lateral flow of electrical current at least in the exposed zone of the substrate. The lateral flow of current and the chemically reactive substance alter the substrate in at least the exposed zone.Type: GrantFiled: March 22, 2019Date of Patent: December 27, 2022Assignee: UNIVERSITE CATHOLIQUE DE LOUVAINInventors: Gilles Scheen, Jean-Pierre Raskin, Jonathan Rasson
-
Publication number: 20220395204Abstract: A device (100) having a proximal end (20) and end a distal end (40) for withdrawal of a liquid sample, fractionation, and separation of one or more fractions comprising: a piston assembly (300) comprising a piston (302) dismountably attached at its proximal end (20) to an actuating rod (350); a container (200) having a body (202) disposed with a cylindrical chamber (204) for slidable movement of the piston (302) therein; wherein the cylindrical chamber (204) is provided at the distal end (40) with a resealable septum (410) for co-operation with a puncture needle assembly (600) for withdrawal of the liquid sample, an at the proximal end (20) with a stop member (206), which stop member (206) limits movement of the piston (300) in a proximal direction, wherein the container body (202) is dimensioned to fit inside a centrifuge rotor, and is configured for breakability into two parts at a temperature of 0 deg C. or lower at a breakable zone (210).Type: ApplicationFiled: November 21, 2020Publication date: December 15, 2022Applicants: UNIVERSITÉ CATHOLIQUE DE LOUVAIN, MEDI-LINE SAInventors: Jean-Luc BALLIGAND, Irina LOBYSHEVA, Nancy VAN OVERSTRAETEN, Jonathan MAIRE, Jean MEENS, Patrick MERKEN
-
Publication number: 20220347111Abstract: A lipid nanocapsule for oral administration including a solid lipid outer shell and a lipophilic liquid inner core having reverse micelles loaded with one or more incretin mimetics. Also, a method for treating and/or preventing a disorder associated with a GLP-1 dysfunction, the method including a step of administering the therapeutically effective amount of the lipid to a subject in need thereof.Type: ApplicationFiled: May 27, 2020Publication date: November 3, 2022Applicant: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Ana BELOQUI, Yining XU, Véronique PRÉAT, Patrice CANI